Respiratory pathogens, such as the Influenza virus and Respiratory Syncytial Virus (RSV), remain a significant disease burden globally causing high levels of acute respiratory infections, morbidity and mortality. Human challenge studies have played and continue to play an important role in the development of respiratory virus vaccines and treatments. hVIVO’s new facility located in Canary Wharf, London, boasts the largest commercial Phase II human challenge trial facility, which contributes substantially to expediting this development and subsequent approvals of novel vaccines and treatments to meet the ongoing need for interventions for significant respiratory disease burden.
